Traitements5programmes
Essais1liés
Publications5liées
SourceDBlocale

Traitements

5
MoléculeIndication / populationPhaseObjectifPaysRésultat
Part A: TRV250-20mg/mlA trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to induce an immediate headache of short duration (under 30 minutes), known as the "GTN immediate headache" Migraine Phase 1 À vérifier United Kingdom À vérifier
Part B: TRV250 Dose 1A trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to induce an immediate headache of short duration (under 30 minutes), known as the "GTN immediate headache" Migraine Phase 1 À vérifier United Kingdom À vérifier
Part B: TRV250 Dose 2A trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to induce an immediate headache of short duration (under 30 minutes), known as the "GTN immediate headache" Migraine Phase 1 À vérifier United Kingdom À vérifier
Part B: TRV250 Dose 3A trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to induce an immediate headache of short duration (under 30 minutes), known as the "GTN immediate headache" Migraine Phase 1 À vérifier United Kingdom À vérifier
Part A: TRV250-20mg/mlA trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to induce an immediate headache of short duration (under 30 minutes), known as the "GTN immediate headache" Migraine Phase 1 À vérifier United Kingdom À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
Part A: TRV250-20mg/ml Migraine Phase 1 NCT04201080 A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250 TERMINATED

Publications

5
MoléculeIndication / populationTitreJournalDate
Part A: TRV250-20mg/ml Prescription of cardiovascular drugs in the French ODIN cohort of heart failure patients according to age and type of chronic heart failure. Archives of cardiovascular diseases
Part A: TRV250-20mg/ml Socioeconomic factors and mortality in diastolic heart failure. European journal of clinical investigation
Part B: TRV250 Dose 1 A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects. CNS drugs
Part A: TRV250-20mg/ml Outbreak of hepatitis A infection associated with the consumption of frozen berries, Ireland, 2013--linked to an international outbreak. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Part A: TRV250-20mg/ml Investigation of a foodborne outbreak of Shigella sonnei in Ireland and Northern Ireland, December 2016: the benefits of cross-border collaboration and commercial sales data. Public health